Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5698558 | CHATTEM SANOFI | Methods for treating allergic disorders using optically pure (-) cetirizine |
Jul, 2013
(10 years ago) | |
US5698558 (Pediatric) | CHATTEM SANOFI | Methods for treating allergic disorders using optically pure (-) cetirizine |
Jan, 2014
(10 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Pediatric Exclusivity(PED) | Feb 21, 2013 |
New Patient Population(NPP) | Aug 21, 2012 |
Market Authorisation Date: 28 January, 2008
Treatment: Relief of symptoms associated with seasonal and perennial allergic rhinitis
Dosage: SOLUTION;ORAL; TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8633194 | CHATTEM SANOFI | Pharmaceutical composition of piperazine derivatives |
Oct, 2027
(3 years from now) |
Market Authorisation Date: 31 January, 2017
Treatment: NA
Dosage: SOLUTION;ORAL